Search results for "Expression"

showing 10 items of 5168 documents

Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study.

2013

4021 Background: In the EXPAND study adding cetuximab to first-line capecitabine and cisplatin chemotherapy (CT) failed to improve clinical outcome in patients (pts) with advanced gastric or gastroesophageal junction cancer. This analysis assessed treatment outcome according to tumor HER2 status (a pre-defined subgroup) and EGFR expression in EXPAND study pts. Methods: Tumor HER2 status was determined primarily by immunohistochemistry (IHC), HER2 +ve tumors were IHC 3+ or IHC 2+ and fluorescence in situ hybridization (FISH) +ve. EGFR expression was assessed by IHC. A continuous scoring system (scale of 0–300) was used to determine the level of EGFR expression. Biomarker status was correlat…

OncologyCisplatinCancer ResearchChemotherapymedicine.medical_specialtyCetuximabbusiness.industrymedicine.medical_treatmentAdvanced gastric cancerEgfr expressionCapecitabineOncologyGastro-Internal medicinemedicineIn patientbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

2010

An important molecular target for metastatic CRC treatment is the epidermal growth factor receptor (EGFR). Many potential biomarkers predictive of response to anti-EGFR monoclonal antibodies (cetuximab and panitumumab) have been retrospectively evaluated, including EGFR activation markers and EGFR ligands activation markers. With regard to the "negative predictive factors" responsible for primary or intrinsic resistance to anti-EGFR antibodies a lot of data are now available. Among these, KRAS mutations have emerged as a major predictor of resistance to panitumumab or cetuximab in the clinical setting and several studies of patients receiving first and subsequent lines of treatment have sho…

OncologyColorectal cancerSettore MED/06 - Oncologia MedicaCetuximabDrug resistancemedicine.disease_causeEpidermal growth factor receptorEGFR; KRAS; Driver mutations; Monoclonal antibodiesCetuximabbiologyPanitumumabAntibodies MonoclonalGeneral MedicinePrognosisAntibodies Anti-IdiotypicErbB ReceptorsGene Expression Regulation NeoplasticOncologyMonoclonalKRASColorectal Neoplasmsmedicine.drugProto-Oncogene Proteins B-rafmedicine.medical_specialtymedicine.drug_classEGFRMonoclonal antibodyAntibodies Monoclonal HumanizedProto-Oncogene Proteins p21(ras)Predictive Value of TestsInternal medicineProto-Oncogene ProteinsmedicineBiomarkers TumorKRASPanitumumabHumansRadiology Nuclear Medicine and imagingneoplasmsbusiness.industryPTEN PhosphohydrolaseMembrane ProteinsDriver mutationmedicine.diseasedigestive system diseasesDrug Resistance NeoplasmMutationCancer researchbiology.proteinras ProteinsMonoclonal antibodiesbusiness
researchProduct

Nm-23-H1 expression does not predict clinical survival in colorectal cancer patients

2003

The gene Nm23, which encodes for a nucleoside diphosphate kinase, has been defined as a metastasis-suppressor gene because of the inverse correlation between its expression and the metastatic capacity of the tumor cells. For colorectal cancer, however, the findings are equivocal. The aim of our study was to assess, in 160 patients undergoing surgery for colorectal cancer (CRC), the expression of the Nm23-H1 protein and to evaluate its possible associations with traditional clinicopathologic variables, with DNA-ploidy and proliferative activity (S-phase fraction, SPF), and with disease-free and overall survival of patients. Nm23-H1 expressions were evaluated on paraffin-embedded tissue by im…

OncologyCytoplasmCancer Researchmedicine.medical_specialtyPathologyTime FactorsSettore MED/06 - Oncologia MedicaColorectal cancerBiologyDisease-Free SurvivalS PhaseInternal medicineNm23-H1 expressionmedicineHumansClinical significancePloidiesModels GeneticOncogeneCancerExonsGeneral MedicineNM23 Nucleoside Diphosphate KinasesCell cycleFlow CytometryPrognosismedicine.diseaseImmunohistochemistryColorectal cancerMolecular medicineOncologyTumor progressionNucleoside-Diphosphate KinaseProtein BiosynthesisDisease ProgressionImmunohistochemistryColorectal NeoplasmsCell Division
researchProduct

Nuclear and cytoplasmic interaction of pRb2/p130 and ER-β in MCF-7 breast cancer cells

2006

Estrogens exhibit important biological functions and influence several pathological processes of hormone-dependent diseases. The biological actions of estrogens require their interaction with two estrogen receptors (ER-alpha and ER-beta), which are ligand-dependent transcription factors. ER-alpha and ER-beta exhibit distinct tissue expression patterns as well as show different patterns of gene regulation. In addition, it has been suggested that ER-beta works as a counter partner of ER-alpha through inhibition of the transactivating functions of ER-alpha. For instance, ER-beta seems to play a different role in breast tumorigenesis than ER-alpha, as ER-beta decreased expression in breast canc…

OncologyCytoplasmmedicine.medical_specialtyMolecular Sequence DataEstrogen receptorBreast NeoplasmsEstrogen receptorsmedicine.disease_causeBreast cancerBreast cancerCancer stem cellCell Line TumorInternal medicinemedicineEstrogen Receptor betaHumansImmunoprecipitationGene silencingAmino Acid SequenceTranscription factorBreast cancer; Estrogen receptors; Estrogens; pRb2/130Cell NucleusRegulation of gene expressionRetinoblastoma-Like Protein p130business.industryEstrogensHematologymedicine.diseaseOncologyMCF-7Cancer researchbusinessCarcinogenesispRb2/130
researchProduct

73P microRNA expression profiles of single hormone receptor-positive breast cancers

2020

OncologyExpression (architecture)Hormone receptorbusiness.industrymicroRNACancer researchMedicineHematologybusinessAnnals of Oncology
researchProduct

CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients

2014

Background Neuroblastoma is a pediatric cancer that exhibits a wide clinical spectrum ranging from spontaneous regression in low-risk patients to fatal disease in high-risk patients. The identification of single nucleotide polymorphisms (SNPs) may help explain the heterogeneity of neuroblastoma and assist in identifying patients at higher risk for poor survival. SNPs in the TP53 pathway are of special importance, as several studies have reported associations between TP53 pathway SNPs and cancer. Of note, less than 2% of neuroblastoma tumors have a TP53 mutation at diagnosis. Patients and Methods We selected 21 of the most frequently studied SNPs in the TP53 pathway and evaluated their assoc…

OncologyGenotyping TechniquesMedizinlcsh:MedicineGenome-wide association studyPROGRESSIONSUSCEPTIBILITYBioinformaticsNeuroblastomaCHEMOSENSITIVITYMedicine and Health SciencesMissense mutationlcsh:ScienceOncogene ProteinsCaspase 8N-Myc Proto-Oncogene ProteinMultidisciplinaryCELL-LINENuclear ProteinsCANCERAPOPTOSISGENOTYPEGene Expression Regulation NeoplasticResearch Articlemedicine.medical_specialtySingle-nucleotide polymorphismBiologyN-Myc Proto-Oncogene ProteinPolymorphism Single NucleotideDisease-Free SurvivalMDM2 SNP309Molecular GeneticsNeuroblastomaInternal medicineCASPASE-8medicineGeneticsCancer GeneticsSNPHumansneoplasmsNeoplasm StagingClinical GeneticsP53lcsh:RGene AmplificationCancerInfantBiology and Life Sciencesmedicine.diseasePediatric cancerGeriatricsGenetics of Diseaselcsh:Q
researchProduct

Association of MAPK signaling subtypes with prognostic benefit for bevacizumab in left-sided metastatic colorectal cancer (mCRC) patients treated wit…

2019

3584 Background: We investigated the role of the MAPK pathway by mRNA expression profiles in microarrays of the FIRE-3 trial as it was formerly associated with prognosis. Methods: 451 patients provided eligible mRNA material for subsequent analyses of the MAPK pathway (295 genes). Non-negative matrix factorized (NMF) clustering for normalized mRNA microarray data (Almac Inc, Xcel Array) was performed for 2 to 6 ranks against randomized controls. Linear models with adjustment for multiple testing showed differential gene expression between groups. Single sample gene set enrichment analysis (ssGSEA) was used to compare differentially enriched hallmarks of cancer gene sets. Kaplan Meier metho…

OncologyMAPK/ERK pathwayCancer Researchmedicine.medical_specialtyBevacizumabCetuximabColorectal cancerbusiness.industryMrna expressionmedicine.diseaseLeft sidedMapk signalingOncologyInternal medicinemedicineFOLFIRIbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular progn…

2014

Abstract Purpose: To optimize neuroblastoma treatment stratification, we aimed at developing a novel risk estimation system by integrating gene expression–based classification and established prognostic markers. Experimental Design: Gene expression profiles were generated from 709 neuroblastoma specimens using customized 4 × 44 K microarrays. Classification models were built using 75 tumors with contrasting courses of disease. Validation was performed in an independent test set (n = 634) by Kaplan–Meier estimates and Cox regression analyses. Results: The best-performing classifier predicted patient outcome with an accuracy of 0.95 (sensitivity, 0.93; specificity, 0.97) in the validation coh…

OncologyMaleCancer ResearchMultivariate statisticsmedicine.medical_specialtyKaplan-Meier EstimateBioinformaticsRisk AssessmentNeuroblastomaText miningRisk FactorsInternal medicineNeuroblastomamedicineBiomarkers TumorCluster AnalysisHumansbusiness.industryProportional hazards modelGene Expression ProfilingReproducibility of ResultsRegression analysismedicine.diseasePrognosisClinical trialGene expression profilingGene Expression Regulation NeoplasticOncologyRegression AnalysisFemalebusinessRisk assessmentFollow-Up StudiesClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

Expression of cell cycle markers and human papillomavirus infection in oral squamous cell carcinoma: use of fuzzy neural networks.

2005

Our aim was to evaluate in oral squamous cell carcinoma (OSCC) the relationship between some cell cycle markers and HPV infection, conditionally to age, gender and certain habits of patients, and to assess the ability of fuzzy neural networks (FNNs) in building up an adequate predictive model based on logic inference rules. Eighteen cases of OSCC were examined by immunohistochemistry for MIB-1, PCNA and survivin expression; presence of HPV DNA was investigated in exfoliated oral mucosa cells by nested PCR (nPCR, MY09-MY11/GP5-GP6), and HPV genotype was determined by direct DNA sequencing. Data were analyzed by traditional statistics (TS) and FNNs. HPV DNA was found in 9/18 OSCCs (50.0 %) wi…

OncologyMaleCancer ResearchSurvivinmedicine.disease_causeInhibitor of Apoptosis ProteinsRisk FactorsOral mucosaPapillomaviridaeAged 80 and overCell CycleSmokingHPV infectionAge FactorsAnatomical pathologyCell cycleMiddle AgedImmunohistochemistryNeoplasm Proteinsoral squamous cell carcinomamedicine.anatomical_structureCell Transformation NeoplasticOncologyCarcinoma Squamous CellImmunohistochemistryFemaleMouth NeoplasmscarcinogenesisMicrotubule-Associated ProteinsAdultmedicine.medical_specialtyBiologySex FactorsFuzzy LogicInternal medicineSurvivinmedicineHumanshuman papillomaviruAgedfuzzy neural networkGene Expression ProfilingPapillomavirus Infectionsmedicine.diseaseProliferating cell nuclear antigenstomatognathic diseasesImmunologyDNA Viralbiology.proteinNeural Networks ComputerCarcinogenesisInternational journal of cancer
researchProduct

Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer

2021

Abstract Purpose: The consensus molecular subtypes (CMS) represent a significant advance in the understanding of intertumor heterogeneity in colon cancer. Intratumor heterogeneity (ITH) is the new frontier for refining prognostication and understanding treatment resistance. This study aims at deciphering the transcriptomic ITH of colon cancer and understanding its potential prognostic implications. Experimental Design: We deconvoluted the transcriptomic profiles of 1,779 tumors from the PETACC8 trial and 155 colon cancer cell lines as weighted sums of the four CMSs, using the Weighted In Silico Pathology (WISP) algorithm. We assigned to each tumor and cell line a combination of up to three …

OncologyMaleCancer Researchmedicine.medical_specialtyMultivariate analysisColorectal cancer[SDV]Life Sciences [q-bio]CellContext (language use)[SDV.CAN]Life Sciences [q-bio]/CancerBiologyTranscriptome[SDV.CAN] Life Sciences [q-bio]/CancerInternal medicineCell Line TumormedicineTumor MicroenvironmentHumansTreatment resistancehealth care economics and organizationsAgedbusiness.industryGene Expression ProfilingHazard ratiomedicine.diseasePrognosisSurvival Rate[SDV] Life Sciences [q-bio]medicine.anatomical_structureOncologyColonic NeoplasmsFemalePersonalized medicinebusiness
researchProduct